Pharma Pioneer

Expert Systems and Eilean Therapeutics Launch First Clinical Trial of Balamenib, a Promising Menin Inhibitor

19 May 2024
2 min read

AI-driven drug discovery firm Expert Systems has reached a key milestone with its partner, Eilean Therapeutics, by initiating the first phase of clinical trials for balamenib (ZE63-0302), a targeted menin-KMT2A inhibitor. The trial is conducted under the Australian TGA's CTN program. Bill Farley, Expert Systems' Chief Business Officer, highlighted balamenib's superior pre-clinical profile, emphasizing its safety, tolerability, and suitability for outpatient use, which are significant over other drugs in its class. The development of balamenib was expedited through Expert Systems' advanced AI platform.
Eilean Therapeutics, backed by Orbimed, Torrey Pines Investment, and Dr. John C. Byrd, is focused on developing innovative treatments for various cancers, utilizing Expert Systems' AI technology to enhance the efficiency of the drug discovery and development process.
Balamenib, an oral medication, has shown potent inhibition of menin in both cell line and xenograft model studies. It is particularly effective when combined with eiletoclax and lomonitinib, drugs developed by Eilean Therapeutics targeting BCL-2 and pan FLT3/IRAK4 respectively. The drug has demonstrated a better safety profile, lacks QTc prolongation, and does not interact with cytochrome P450 3A4 metabolism. It also has a lower risk of resistance associated with menin "hot spot" mutations.
Expert Systems provides a full spectrum of preclinical drug discovery services, from target identification to toxicology, using a hybrid AI system that integrates proprietary and public databases. The company has played a significant role in the establishment and management of numerous R&D programs and startup companies.
Eilean Therapeutics is a biopharmaceutical company that collaborates with Orbimed, Torrey Pines Investment, and Dr. John C. Byrd to identify novel small molecule inhibitors for hematologic and solid cancers. The company uses Expert Systems' AI platform and its partners' data and expertise to design and develop advanced therapies, aiming to create new treatments for cancer patients.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Faron's Webcast on BEXMAB Phase 1 Data and Bexmarilimab Updates
Pharma Pioneer
2 min read
Faron's Webcast on BEXMAB Phase 1 Data and Bexmarilimab Updates
19 May 2024
Faron Pharmaceuticals, a biopharmaceutical firm specializing in innovative immunotherapies, has announced the scheduling of a virtual BEXMAB study update session.
Read →
Gynica Initiates Innovative IntraVag© Clinical Trial for Endometriosis Treatment
Pharma Pioneer
3 min read
Gynica Initiates Innovative IntraVag© Clinical Trial for Endometriosis Treatment
19 May 2024
The clinical trial will explore Gynica's proprietary cannabinoid-based formulations, which are administered intravaginally, leveraging the therapeutic potential of cannabinoids in women's health.
Read →
Positive Phase 1 Results for IMM-1-104 in RAS-Mutant Tumor Clinical Trial
Pharma Pioneer
3 min read
Positive Phase 1 Results for IMM-1-104 in RAS-Mutant Tumor Clinical Trial
19 May 2024
Immuneering Corporation has reported encouraging results from the Phase 1 segment of its Phase 1/2a clinical trial for IMM-1-104.
Read →
RECCE® 327 Phase I/II Trial Advances with Next Dosage Cohort for UTIs and Urosepsis
Pharma Pioneer
2 min read
RECCE® 327 Phase I/II Trial Advances with Next Dosage Cohort for UTIs and Urosepsis
19 May 2024
Recce Pharmaceuticals Ltd, a company focused on developing synthetic anti-infectives to combat antibiotic resistance and emerging viral threats, has initiated a new phase in its clinical trials.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.